ADAM17 and cancer: In LUAD, KRAS mutation contributes to the phosphorylation of ADAM17 threonine via p38 MAPK, thereby driving ADAM17 to selectively promote its substrate IL-6R shedding and subsequent ERK1/2 MAPK-IL-6-mediated trans-signal transduction, leading to malignant progression of the cancer (152).